

**ALLEGATO C**  
**CURRICULUM VITAE**

FORMATO EUROPEO  
PER IL  
CURRICULUM  
VITAE



**INFORMAZIONI PERSONALI**

*Nome e Cognome*

Paolo Ceppi

*Data di nascita*

*Telefono*

*Telefono cellulare*

*Indirizzo posta elettronica*

**Indirizzo Pec**

*Incarico attuale*

Associate Professor,  
Department of Biochemistry and Molecular Biology  
University of Southern Denmark

**ISTRUZIONE  
E FORMAZIONE**

• *Date (da – a)*

02/2011 PhD in Cancer Pathology, Doctorate School of Biomedical Sciences and Human Oncology, University of Turin, Italy.

07/2004 Master in Molecular Biology, University of Turin, Italy.

• *Nome e tipo di istituto  
di istruzione o formazione*

• *Qualifica conseguita*

**ESPERIENZA LAVORATIVA**

• *Date (da – a)*

• *Nome e indirizzo del datore di lavoro*

From 08/2019 Associate Professor of Cell Biology, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.

From 08/2015 Junior Research Group Leader, Interdisciplinary Center for Clinical Research (IZKF), Universitätsklinikum Erlangen, Germany.

03/2011 – 06/2015 Postdoctoral fellow at the R.H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, USA.

02/2009 – 12/2009 Visiting PhD student at the Medical Faculty Mannheim, University of Heidelberg, Germany.

01/2007 – 12/2010 PhD student at San Luigi Hospital, University of Turin, Italy.

12/2004 – 06/2005 Visiting training fellow at Norris Cancer Center, University of Southern California, Los Angeles, USA.

09/2004 – 12/2006 Research assistant at San Luigi Hospital, University of Turin, Italy.

• *Tipo di azienda o settore*

• *Tipo di impiego*

• *Principali mansioni e responsabilità*

.

**MADRELINGUA**

**Italian**

ALTRE LINGUE

**English**

**ALTRO** (PARTECIPAZIONE A CONVEGNI, SEMINARI, PUBBLICAZIONI, COLLABORAZIONI A RIVISTE,ECC. ED OGNI ALTRA INFORMAZIONE CHE IL COMPILANTE RITIENE DI DOVER PUBBLICARE)

### Professional Memberships

- 2018- International Society of Cancer Metabolism (ISCaM).  
2016 - International Association for the Study of Lung Cancer (IASLC).  
2010 - American Association for Cancer Research.

### Publication overview

**48** peer-reviewed research articles plus **1** book chapter,

**24** of which as first, co-first or last author,

**15** as corresponding author.

**4949** citations, more than **60%** from papers as first or last author,

H-Index: **31** (source: Google-Scholar).

### Peer-reviewed articles:

1.Zhang S, Yun D, Yang H, Eckstein M, Elbait GD, Zhou Y, Lu Y, Yang H, Zhang J, Dörflein I, Britzen-Laurent N, Pfeffer S, Stemmler MP, Dahl A, Mukhopadhyay D, Chang D, He H, Zeng S, Lan B, Frey B, Hampel C, Lentsch E, Gollavilli PN, Büttner C, Ekici AB, Biankin A, Schneider-Stock R, **Ceppi P**, Grützmann R, Pilarsky C. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. *Cell Death Discovery* 2024 Mar 9;10(1):124.

2.Ramesh V, Gollavilli PN, Pinna L, Siddiqui MA, Martinez Turtos A, Napoli F, Antonelli Y, Leal-Egaña A, Havelund JF, Toftholm Jakobsen S, Le Boiteux E, Volante M, Færgeman NJ, Jensen ON, Siersbæk R, Somyajit K and **Ceppi P**. Propionate reinforces epithelial identity and reduces aggressiveness of lung carcinoma. *EMBO Molecular Medicine*, 2023 Sep 28:e17836. doi: 10.15252/emmm.202317836, **as corresponding author**.

3.Schuhwerk H, Kleemann J, Gupta P, van Roey R, Armstark I, Kreileder M, Feldker N, Ramesh V, Hajjaj Y, Fuchs K, Mahapatro M, Hribersek M, Volante M, Groenewoud A, Engel FB, **Ceppi P**, Eckstein M, Hartmann A, Müller F, Kroll T, Stemmler MP, Brabletz S, Brabletz T. The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. *Cell Reports*, 2022;41(11):111819.

4.Parma B, Wurdak H, **Ceppi P**. Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins. *Drug Resistance Updates*, 2022; 65:100888, **as corresponding author**.

5.Ertekin Ö, Monavari M, Krüger R, Fuentes-Chandía M, Parma B, Letort G, Tripal P, Boccaccini AR, Bosserhoff AK, **Ceppi P**,Kappelmann-Fenzl M, Leal-Egaña A.3D hydrogel- based microcapsules as an in vitro model to study tumorigenicity, cell migration and drug resistance. *Acta Biomaterialia*, 2022 Feb.

6.Parma B, RameshV, Gollavilli PN, Siddiqui A, Pinna L, Schwab A, Marschall S, Zhang S, Pilarsky C, Napoli F, Volante M, Urbanczyk S, Mielenz D, Schröder HD, Stemmler M, Wurdak H, **Ceppi P**. Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. *Journal of Experimental and Clinical Cancer Research*, 2021;40(1):248. doi: 10.1186/s13046-021-02049-8, **as corresponding author**.

7.Fuentes-Chandía M, Vierling A, Kappelmann-Fenzl M, Monavari M, Letort G, Höne L, Parma B, Khan Antara S, ErtekinÖ, Palmisano R, Dong M, Böpple K, Boccaccini AR, **Ceppi P**, Bosserhoff AK, Leal-Egaña A. 3D Spheroids Versus 3D Tumor-Like Microcapsules: Confinement and Mechanical Stress May Lead to the Expression of Malignant Responses in Cancer Cells.*Advanced Biology*, 2021 Jul;5(7):e2000349. Epub 2021 May 7.

